Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Wegovy is the version of semaglutide marketed to treat obesity by the longtime market leader in sales of GLP-1 diabetes and obesity treatments Novo Nordisk (NASDAQ Copenhagen: NOVO-B) , which also markets semaglutide to treat type 2 diabetes under the name Ozempic
Funding This study did not receive any funding or financial support
Medical supervision ensures proper dosing, purity verification, and ongoing monitoring for maximum benefit and minimal risk
Estrogen has anti-inflammatory effects, so its decline can increase inflammatory markers
Speak With Our Team About GLP-1 Supply Medical Professionals Only Verified Accounts Required All Accounts Subject to Verification
US$ 26.38
US$ 23.89
US$ 24.52
US$ 21.30
US$ 26.65
US$ 26.82
US$ 26.63
US$ 25.09
